RxDoctor Payments Data

David Stornelli, MD

Internal Medicine · Rochester, NYNPI 1942224688

Payments from drug & device makers

$9,410in general payments, 2019–2025

Across 668 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • GSK$991
  • Pfizer$940
  • Novo Nordisk$924
  • AbbVie$724
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$9,405100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,410 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$29,980
Medicare patients
85
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$164,464
TrulicityDulaglutide139$142,651
EliquisApixaban127$136,805
JardianceEmpagliflozin52$57,916
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$54,770
FarxigaDapagliflozin Propanediol26$28,870
MounjaroTirzepatide23$23,416
XareltoRivaroxaban21$18,491
Repatha SureclickEvolocumab17$12,177
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,341
MyrbetriqMirabegron16$10,123
NeuproRotigotine11$9,326
Lantus SolostarInsulin Glargine,hum.Rec.Anlog81$8,273
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$8,127
Rosuvastatin Calcium322$7,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,335$166,067162 claims
Novo NordiskOzempic$924$164,464144 claims
PfizerEliquis$940$136,805127 claims
Boehringer IngelheimJardiance$513$57,91652 claims
GSKTrelegy Ellipta$991$54,77077 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,205$39,21042 claims
Johnson & JohnsonXarelto$585$18,49121 claims
Astellas Pharma US IncMyrbetriq$165$10,12316 claims
AbbVieSynthroid$724$3,31027 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$227$3,26913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →